In both the research and clinical setting, being able to identify and collect biologically meaningful data related to productive antitumor responses is of paramount importance when trying to evaluate the efficacy of a particular cell-based cancer immunotherapy. Historically, this has been a major bottleneck for investigators as many of the available technologies provide readouts of limited utility due to constraints surrounding experimental throughput, end-point readouts where a single measurement is performed after some arbitrary fixed amount time, and the inability to link multi-modal data back to single cells of interest. In his talk, Dr. Anthony E. Zamora will highlight current research being performed in his lab that highlight how the Beacon platform and real-time biological readouts can be leveraged to help unravel the biological complexities that exist across many of today’s leading cell-based therapies for cancer and how multi-modal data can be used to gain insight into the biological parameters that are associated with clinical efficacy.